ELVN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 29.20%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $44,855,724.13

Enliven Therapeutics Insider Trading History Chart

Enliven Therapeutics Share Price & Price History

^$27.85

▼ -0.54 (-1.90%)

As of 10/31/2024 01:00 AM ET

Days: 30 | 90 | 365

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.

Enliven Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/28/2024	Benjamin Hohl	CFO	Sell	6,250	$28.56	$178,500.00
10/18/2024	Anish Patel	COO	Sell	716	$30.00	$21,480.00	343,311
10/18/2024	Benjamin Hohl	CFO	Sell	814	$30.00	$24,420.00
10/18/2024	Joseph P Lyssikatos	Insider	Sell	847	$30.00	$25,410.00	1,015,188
10/18/2024	Richard A Heyman	Director	Sell	817	$30.00	$24,510.00	123,673
10/18/2024	Samuel Kintz	CEO	Sell	924	$30.00	$27,720.00	1,002,892
10/15/2024	Richard A Heyman	Director	Sell	1,270	$27.67	$35,140.90	124,490
10/9/2024	Joseph P Lyssikatos	Insider	Sell	37,878	$28.16	$1,066,644.48	1,016,035
10/9/2024	Samuel Kintz	CEO	Sell	16,710	$28.15	$470,386.50	1,003,816
10/8/2024	Rahul D Ballal	Director	Sell	10,420	$28.17	$293,531.40	22,341
10/7/2024	Benjamin Hohl	CFO	Sell	1,270	$27.51	$34,937.70
10/7/2024	Joseph P Lyssikatos	Insider	Sell	2,707	$27.61	$74,740.27	1,067,180
10/7/2024	Samuel Kintz	CEO	Sell	2,730	$27.50	$75,075.00	1,033,793
10/4/2024	Benjamin Hohl	CFO	Sell	10,218	$27.51	$281,097.18
10/4/2024	Joseph P Lyssikatos	Insider	Sell	7,522	$27.51	$206,930.22	1,069,887
10/4/2024	Richard A Heyman	Director	Sell	2,825	$27.51	$77,715.75	125,760
10/4/2024	Samuel Kintz	CEO	Sell	12,206	$27.51	$335,787.06	1,036,523
10/1/2024	Joseph P Lyssikatos	Insider	Sell	527	$27.54	$14,513.58	1,077,409
10/1/2024	Richard A Heyman	Director	Sell	518	$27.54	$14,265.72	128,585
10/1/2024	Samuel Kintz	CEO	Sell	526	$27.54	$14,486.04	1,048,729
9/30/2024	Benjamin Hohl	CFO	Sell	2,000	$25.33	$50,660.00
9/27/2024	Benjamin Hohl	CFO	Sell	4,250	$24.27	$103,147.50
8/29/2024	Joseph P Lyssikatos	Insider	Sell	12,000	$22.49	$269,880.00	1,077,936
8/27/2024	Benjamin Hohl	CFO	Sell	4,250	$22.54	$95,795.00
8/26/2024	Samuel Kintz	CEO	Sell	12,000	$22.89	$274,680.00	1,049,255
8/15/2024	Richard A Heyman	Director	Sell	1,270	$23.25	$29,527.50	130,373
7/31/2024	Benjamin Hohl	CFO	Sell	991	$27.53	$27,282.23
7/31/2024	Joseph P Lyssikatos	Insider	Sell	3,099	$27.56	$85,408.44	1,089,936
7/31/2024	Richard A Heyman	Director	Sell	1,702	$27.51	$46,822.02	131,643
7/31/2024	Samuel Kintz	CEO	Sell	2,270	$27.56	$62,561.20	1,061,255
7/29/2024	Benjamin Hohl	CFO	Sell	5,250	$26.68	$140,070.00
7/29/2024	Joseph P Lyssikatos	Insider	Sell	12,000	$26.70	$320,400.00	1,093,035
7/25/2024	Samuel Kintz	CEO	Sell	12,000	$24.92	$299,040.00	1,063,525
7/15/2024	Anish Patel	COO	Sell	30,978	$25.05	$775,998.90	345,574
7/15/2024	Richard A Heyman	Director	Sell	1,270	$24.80	$31,496.00	133,345
7/12/2024	Anish Patel	COO	Sell	17,475	$25.07	$438,098.25	376,552
7/12/2024	Benjamin Hohl	CFO	Sell	3,000	$25.07	$75,210.00
6/27/2024	Benjamin Hohl	CFO	Sell	4,250	$22.57	$95,922.50
6/25/2024	Samuel Kintz	CEO	Sell	12,000	$21.66	$259,920.00	1,075,525
6/6/2024	Anish Patel	COO	Sell	1,133	$20.06	$22,727.98
5/28/2024	Benjamin Hohl	CFO	Sell	4,250	$23.18	$98,515.00
5/28/2024	Samuel Kintz	CEO	Sell	12,000	$23.18	$278,160.00
5/16/2024	Rishi Gupta	Director	Sell	1,033,300	$22.14	$22,877,262.00	254,814
5/14/2024	Anish Patel	COO	Sell	1,107	$25.00	$27,675.00
5/9/2024	Anish Patel	COO	Sell	260	$25.06	$6,515.60
5/6/2024	Anish Patel	COO	Sell	4,875	$22.72	$110,760.00
5/3/2024	Benjamin Hohl	CFO	Sell	1,000	$22.50	$22,500.00
4/29/2024	Benjamin Hohl	CFO	Sell	3,250	$16.97	$55,152.50
4/29/2024	Joseph P. Lyssikatos	insider	Sell	12,000	$17.92	$215,040.00
4/25/2024	Samuel Kintz	CEO	Sell	12,000	$16.89	$202,680.00
4/15/2024	Richard A Heyman	Director	Sell	1,270	$19.99	$25,387.30	137,155
4/11/2024	Anish Patel	COO	Sell	17,500	$25.03	$438,025.00
4/11/2024	Benjamin Hohl	CFO	Sell	14,000	$24.72	$346,080.00
4/11/2024	Joseph P. Lyssikatos	insider	Sell	30,000	$25.04	$751,200.00
4/11/2024	Rahul D Ballal	Director	Sell	53,400	$23.95	$1,278,930.00	22,341
4/11/2024	Samuel Kintz	CEO	Sell	47,709	$25.04	$1,194,633.36
4/8/2024	Anish Patel	COO	Sell	4,875	$18.60	$90,675.00	2,597
4/4/2024	Rahul D Ballal	Director	Sell	3,485	$19.15	$66,737.75	22,341
4/1/2024	Joseph P. Lyssikatos	insider	Sell	12,000	$18.60	$223,200.00
4/1/2024	Rahul D Ballal	Director	Sell	3,237	$19.08	$61,761.96	22,341
3/27/2024	Benjamin Hohl	CFO	Sell	3,250	$18.25	$59,312.50
3/25/2024	Samuel Kintz	CEO	Sell	12,000	$17.56	$210,720.00
3/19/2024	Richard A Heyman	Director	Sell	1,270	$14.50	$18,415.00	143,470
3/6/2024	Anish Patel	COO	Sell	4,875	$15.64	$76,245.00	7,472
2/29/2024	Joseph P. Lyssikatos	insider	Sell	12,000	$16.42	$197,040.00
2/27/2024	Benjamin Hohl	CFO	Sell	3,250	$16.97	$55,152.50
2/15/2024	Richard A Heyman	Director	Sell	1,270	$17.42	$22,123.40	144,740
2/6/2024	Anish Patel	COO	Sell	4,875	$15.11	$73,661.25	12,347
1/31/2024	5Am Partners Vi, Llc	Major Shareholder	Sell	500,000	$15.00	$7,500,000.00	771,983
1/30/2024	Richard A Heyman	Director	Sell	1,270	$16.41	$20,840.70	146,010
1/29/2024	Benjamin Hohl	CFO	Sell	3,250	$15.81	$51,382.50
1/29/2024	Joseph P. Lyssikatos	insider	Sell	12,000	$15.85	$190,200.00
1/25/2024	Samuel Kintz	CEO	Sell	12,000	$15.69	$188,280.00
1/22/2024	Anish Patel	COO	Sell	4,875	$15.13	$73,758.75	17,222
1/2/2024	Anish Patel	COO	Sell	11,000	$15.00	$165,000.00	22,097
1/2/2024	Benjamin Hohl	CFO	Sell	9,383	$15.01	$140,838.83
12/26/2023	Anish Patel	COO	Sell	102	$15.01	$1,531.02	35,637
12/26/2023	Benjamin Hohl	CFO	Sell	100	$15.00	$1,500.00
12/26/2023	Samuel Kintz	CEO	Sell	12,000	$14.64	$175,680.00
12/22/2023	Anish Patel	COO	Sell	983	$15.03	$14,774.49	35,739
12/22/2023	Benjamin Hohl	CFO	Sell	1,030	$15.07	$15,522.10
12/22/2023	Samuel Kintz	CEO	Sell	8,175	$13.05	$106,683.75
12/21/2023	Joseph P. Lyssikatos	insider	Sell	20	$13.00	$260.00
12/21/2023	Richard A Heyman	Director	Sell	7	$13.00	$91.00	147,448
12/20/2023	Samuel Kintz	CEO	Sell	7,779	$13.01	$101,204.79
12/19/2023	Joseph P. Lyssikatos	insider	Sell	200	$13.00	$2,600.00
12/19/2023	Richard A Heyman	Director	Sell	255	$13.00	$3,315.00	149,565
11/3/2023	Joseph P. Lyssikatos	insider	Sell	8,546	$13.08	$111,781.68
11/3/2023	Samuel Kintz	CEO	Sell	8,026	$13.08	$104,980.08
9/29/2023	Joseph P. Lyssikatos	insider	Sell	12,000	$13.62	$163,440.00
9/26/2023	5Am Partners Vi, Llc	Major Shareholder	Sell	197,500	$15.00	$2,962,500.00	854,796
9/25/2023	Samuel Kintz	CEO	Sell	12,000	$13.81	$165,720.00
8/24/2023	5Am Partners Vi, Llc	Major Shareholder	Sell	440,000	$16.00	$7,040,000.00	887,507

Urgent: This election is rigged

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.

SEC Filings (Institutional Ownership Changes) for Enliven Therapeutics (NASDAQ:ELVN)

95.08% of Enliven Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Enliven Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
10/25/2024	China Universal Asset Management Co. Ltd.	9,085	$0.23M	0.0%	+64.4%	0.019%
10/10/2024	Exchange Traded Concepts LLC	7,483	$0.19M	0.0%	-60.3%	0.016%
10/3/2024	SG Americas Securities LLC	10,013	$0.26M	0.0%	N/A	0.021%
8/15/2024	The Manufacturers Life Insurance Company	13,764	$0.32M	0.0%	N/A	0.029%
8/14/2024	Marshall Wace LLP	192,100	$4.49M	0.0%	N/A	0.408%
8/14/2024	Logos Global Management LP	595,000	$13.91M	1.1%	-62.2%	1.265%
8/14/2024	HighVista Strategies LLC	119,789	$2.80M	1.0%	-5.6%	0.255%
8/8/2024	First Turn Management LLC	413,243	$9.66M	1.6%	N/A	0.879%
8/8/2024	Nicholas Investment Partners LP	56,072	$1.31M	0.1%	N/A	0.119%
8/8/2024	American Century Companies Inc.	27,651	$0.65M	0.0%	+44.7%	0.059%
8/6/2024	Quest Partners LLC	1,592	$37K	0.0%	+87.3%	0.003%
8/1/2024	Rhumbline Advisers	49,627	$1.16M	0.0%	+29.9%	0.105%
7/26/2024	Bank of New York Mellon Corp	114,109	$2.67M	0.0%	+49.2%	0.243%
5/16/2024	California State Teachers Retirement System	19,141	$0.34M	0.0%	-5.8%	0.041%
5/16/2024	Janus Henderson Group PLC	713,911	$12.60M	0.0%	+74.8%	1.519%
5/16/2024	Blackstone Inc.	25,191	$0.44M	0.0%	N/A	0.054%
5/15/2024	Baker BROS. Advisors LP	114,833	$2.02M	0.0%	N/A	0.244%
5/14/2024	EntryPoint Capital LLC	9,510	$0.17M	0.1%	N/A	0.020%
5/10/2024	Vanguard Group Inc.	1,183,266	$20.81M	0.0%	-3.9%	2.517%
5/7/2024	SG Americas Securities LLC	9,430	$0.17M	0.0%	-30.2%	0.020%
4/29/2024	China Universal Asset Management Co. Ltd.	7,952	$0.14M	0.0%	+67.0%	0.017%
2/13/2024	Tower Research Capital LLC TRC	5,485	$76K	0.0%	-18.8%	0.013%
2/6/2024	AJOVista LLC	2,046	$28K	0.0%	N/A	0.005%
2/6/2024	Swiss National Bank	36,473	$0.51M	0.0%	-10.3%	0.089%
1/24/2024	Mirae Asset Global Investments Co. Ltd.	12,305	$0.17M	0.0%	+9.1%	0.030%
1/24/2024	China Universal Asset Management Co. Ltd.	4,763	$66K	0.0%	N/A	0.012%
1/12/2024	SG Americas Securities LLC	13,501	$0.19M	0.0%	+17.8%	0.033%
1/5/2024	Exchange Traded Concepts LLC	8,708	$0.12M	0.0%	+34.0%	0.021%
12/6/2023	Citigroup Inc.	3,347	$46K	0.0%	-69.1%	0.008%
11/13/2023	FMR LLC	3,676,213	$50.22M	0.0%	-8.1%	8.923%
11/8/2023	Swiss National Bank	40,673	$0.56M	0.0%	-17.3%	0.099%
11/7/2023	Barclays PLC	13,629	$0.19M	0.0%	-8.1%	0.033%
10/23/2023	BML Capital Management LLC	50,000	$0.68M	0.6%	-32.6%	0.121%
10/13/2023	SG Americas Securities LLC	11,460	$0.16M	0.0%	N/A	0.028%
8/15/2023	HighVista Strategies LLC	121,073	$2.47M	1.1%	N/A	0.294%
8/15/2023	Commodore Capital LP	2,348,272	$47.93M	5.4%	+35.6%	5.707%
8/11/2023	VR Adviser LLC	2,230,127	$45.52M	7.3%	+0.7%	5.423%
8/10/2023	Metropolitan Life Insurance Co NY	1,279	$26K	0.0%	N/A	0.003%
8/4/2023	American International Group Inc.	11,235	$0.23M	0.0%	N/A	0.027%
8/3/2023	Bank of New York Mellon Corp	80,924	$1.65M	0.0%	+429.1%	0.197%
8/2/2023	Bank of Montreal Can	191,893	$3.95M	0.0%	N/A	0.467%
7/24/2023	BML Capital Management LLC	74,232	$1.52M	1.4%	-65.0%	0.181%
7/20/2023	Exchange Traded Concepts LLC	6,934	$0.14M	0.0%	N/A	0.017%
7/18/2023	Denali Advisors LLC	9,900	$0.20M	0.1%	N/A	0.024%
6/1/2023	Prelude Capital Management LLC	34,062	$40K	0.0%	N/A	0.519%
5/16/2023	Fairmount Funds Management LLC	1,924,938	$42.16M	7.2%	N/A	29.353%
5/16/2023	Boxer Capital LLC	710,644	$15.56M	0.8%	N/A	10.836%
5/15/2023	Commodore Capital LP	1,731,365	$37.92M	5.8%	N/A	26.401%
5/15/2023	Logos Global Management LP	401,229	$8.79M	1.3%	N/A	6.118%
5/12/2023	Mirabella Financial Services LLP	11,670	$0.26M	0.0%	N/A	0.178%
5/11/2023	FMR LLC	3,163,482	$69.28M	0.0%	N/A	48.239%
4/20/2023	Dorsey Wright & Associates	1,237	$27K	0.0%	N/A	0.019%

Data available starting January 2016

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Today's Range

Now: $27.85

$27.76

$29.05

50 Day Range

MA: $25.05

$21.44

$29.00

52 Week Range

Now: $27.85

$9.80

$30.03

Volume

278,175 shs

Average Volume

258,530 shs

Market Capitalization

$1.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Who are the company insiders with the largest holdings of Enliven Therapeutics?: Enliven Therapeutics' top insider investors include:
Joseph P Lyssikatos (Insider)
Samuel Kintz (CEO)
5Am Partners Vi, Llc (Major Shareholder)
Anish Patel (COO)
Rishi Gupta (Director)
Richard A Heyman (Director)
Rahul D Ballal (Director)
Benjamin Hohl (CFO)
Joseph P Lyssikatos (Insider)
Learn More about top insider investors at Enliven Therapeutics.
Who are the major institutional investors of Enliven Therapeutics?: Enliven Therapeutics' top institutional shareholders include:
SG Americas Securities LLC — 0.02%
China Universal Asset Management Co. Ltd. — 0.02%
Exchange Traded Concepts LLC — 0.02%
Learn More about top institutional investors of Enliven Therapeutics stock.
Which institutional investors are selling Enliven Therapeutics stock?: Within the previous quarter, ELVN stock was sold by these institutional investors:
Exchange Traded Concepts LLC
In the previous year, company insiders that have sold Enliven Therapeutics company stock include:
Joseph P Lyssikatos (Insider)
Samuel Kintz (CEO)
5Am Partners Vi, Llc (Major Shareholder)
Anish Patel (COO)
Rishi Gupta (Director)
Richard A Heyman (Director)
Rahul D Ballal (Director)
Benjamin Hohl (CFO)
Joseph P Lyssikatos (Insider)
Learn More investors selling Enliven Therapeutics stock.
Which institutional investors are buying Enliven Therapeutics stock?: During the previous quarter, ELVN stock was acquired by institutional investors including:
SG Americas Securities LLC
China Universal Asset Management Co. Ltd.